The advent of immunogenomics has revolutionized the landscape of precision oncology, offering unprecedented insights into the tumor microenvironment and patient-specific immune responses.
In this webinar, we will explore the integration of immunogenomic profiling into clinical practice, highlighting how it drives tailored therapeutic strategies, from immune checkpoint inhibitors to novel vaccine-based therapies. We will discuss the role of comprehensive assays like OmniSeq® INSIGHT from Labcorp Oncology in uncovering critical biomarkers, optimizing treatment decisions, and enhancing the patient journey from diagnosis to personalized therapy. Attendees will gain a deeper understanding of how immunogenomic reporting is helping patients with complex malignancies. This session is ideal for clinicians, pathologists, and oncologists interested in cutting-edge approaches to precision oncology and personalized medicine.
Director of Laboratory & Bioinformatics R&D, Labcorp Oncology
Dr. Sarabjot Pabla serves as Director of Laboratory & Bioinformatics R&D for Labcorp Oncology. In this role, he oversees the clinical and R&D functions at Buffalo Lab, including Bioinformatics, Data Science and Translational research. He leads scientific collaborations activities with key industry, academia, and pharmaceutical partners, and oversees all computational biology development and implementation of advanced bioinformatics pipelines for NGS diagnostics assays. Dr. Pabla, in the past decade, has extensively studied autoimmunity and later cancer immunity using cutting edge multi-omics approaches. This includes his time at Medical College of Georgia, where he completed his doctorate studies in genomic medicine. During his clinical and translational research career, Dr. Pabla has authored or co-authored several high impact publications with his most highly cited work in the field of predicting response to immunotherapy in solid tumors.
